Close
FINDING CURES TOGETHER<sup>SM</sup>

CIMM Election Results

Congratulations to Weiping Zou, MD, PhD, CIMM Chairperson-elect 2018-2019

Our thanks to Weiping Zou, MD, PhD, and Laurence Zitvogel, MD, PhD, for standing for election and to the membership of CIMM for participating in the election. Congratulations to Dr. Zou for having been elected as CIMM chairperson-elect. Dr. Zou will assume the office of chairperson-elect at the AACR Annual Meeting 2018, April 14-18, 2018, in Chicago, Illinois.

Weiping Zou, MD, PhD
Charles B. de Nancrede Professor
Professor of Surgery, Immunology, Pathology, and Biology
Co-director, Cancer Hematopoiesis and Immunology Program
Co-director, Immunologic Monitoring Core
Director, University of Michigan Surgical Oncology Research Training Program
Director, Translational Research, Department of SurgeryProfessor of Surgery
University of Michigan School of Medicine
Ann Arbor, Michigan, USA

Education:
1997
PhD, University of Paris, Paris, France

Research Interests:
Characterization of the complex immune interactions in the cancer microenvironment holds the key to understanding tumor immunity and designing more effective cancer immunotherapies.
The Zou laboratory has focused on the human cancer microenvironment and demonstrated that the interactions between tumor cells and the host cells foster tumor immunosuppressive networks which results in cancer progression and therapeutic resistance. These studies of cancer infiltrating immune cell subsets and cancer genetic, epigenetic, and metabolic signatures have defined cancer immune phenotypes and allowed for the rational determination of targets within immunosuppressive networks, such as the PD-L1/PD-1 pathway, to treat cancer patients.

Proposed Goals:
It is a great honor and a source of pride for me to now serve as the CIMM chairperson-elect 2018-2019. CIMM-AACR has been the home of many cancer immunologists and oncologists. The major issues facing CIMM are the dwindling size of the NIH RO1 pool, the undirected plethora of immune-based clinical trials, and the insufficient numbers of young tumor immunologists. My goal is to tackle these issues through different strategies:

  • I will encourage and engage the strong lobby effort of CIMM and the AACR to persuade the Congress, funding agencies, and industry that cancer immunology and immunotherapy represents a major untapped science that can lead to breakthrough cancer treatments
    worthy of support.
  • I will work with the CIMM Steering Committee and the AACR to make proactive efforts across the laboratory-clinic divide and facilitate CIMM to actively collaborate with other
    scientific societies including ASCO, AAI, and SITC, in order to explore mechanisms of therapeutic response and resistance, side-effects in patients, and to conduct mechanism-informed clinical trials.
  • I will plan with the CIMM Steering Committee and the AACR to promote the recruitment and motivation of the most broad-minded young national and international scientists from multidisciplines to become tumor immunologists through workshops, meetings, networks,
    and society collaborations.
  • I will ensure that the AACR's defined roles and responsibilities of the CIMM chairperson
    are honored.